Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis

References

• Denton CP. Advances in pathogenesis and treatment of systemic sclerosis. Clin Med (Lond). 2015;15(Suppl 6):s58–s63.10.7861/clinmedicine.15-6-s58
   PubMedGoogle Scholar
• Sato S, Fujimoto M, Hasegawa M, et al. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol. 2004;41(12):1123–1133.10.1016/j.molimm.2004.06.025
   PubMed Web of Science ®Google Scholar
• Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578–583.10.1002/art.v60:2
   PubMed Web of Science ®Google Scholar
• Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12(2):R54.10.1186/ar2965
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SNC, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010;49(2):271–280.10.1093/rheumatology/kep093
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SN. B cells tell scleroderma fibroblasts to produce collagen. Arthritis Res Ther. 2013;15(6):125.10.1186/ar4392
   PubMed Web of Science ®Google Scholar
• François A, Chatelus E, Wachsmann D, et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther. 2013;15(5):R168.10.1186/ar4352
   PubMed Web of Science ®Google Scholar
• Smith V, Piette Y, van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52–57.10.3899/jrheum.120778
   PubMed Web of Science ®Google Scholar
• Fraticelli P, De Vita S, Franzolini N, et al. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. Clin Exp Rheumatol. 2015;33(4 Suppl 91):S160–7.
   PubMed Web of Science ®Google Scholar
• Wu M, Mohan C. B-cells in systemic sclerosis: emerging evidence from genetics to phenotypes. Curr Opin Rheumatol. 2015;27(6):537–541.10.1097/BOR.0000000000000215
   PubMed Web of Science ®Google Scholar
• Bonroy C, Smith V, Deschepper E, et al. Specific antinuclear antibody level changes after B-cell depletion therapy in systemic sclerosis are associated with improvement of skin thickening. J Rheumatol. 2016;43(1):247–249.10.3899/jrheum.150105
   PubMed Web of Science ®Google Scholar
• Mavropoulos A, Simopoulou T, Varna A, et al. Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis. Arthritis Rheumatol. 2016;68(2):494–504.10.1002/art.39437
   PubMed Web of Science ®Google Scholar
• Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188–1194.10.1136/annrheumdis-2013-204522
   PubMed Web of Science ®Google Scholar
• Smith VP, Van Praet JT, Vandooren BR, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193–197.10.1136/ard.2008.095463
   PubMed Web of Science ®Google Scholar
• Valentini G, D’Angelo S, Della Rossa A, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis. 2003;62(9):904–905.10.1136/ard.62.9.904
   PubMed Web of Science ®Google Scholar
• Valentini G, Della Rossa A, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60(6):592–598.10.1136/ard.60.6.592
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–1755.10.1136/annrheumdis-2013-204424
   PubMed Web of Science ®Google Scholar
• Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum. 1979;22(2):130–140.10.1002/(ISSN)1529-0131
   PubMed Web of Science ®Google Scholar
• Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22(7):1281–1285.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr. The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997;40(11):1984–1991.10.1002/(ISSN)1529-0131
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE Jr, Lu JF, et al. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40–66.10.1097/00005650-199401000-00004
   PubMed Web of Science ®Google Scholar
• Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6(2):65–70.
   Web of Science ®Google Scholar
• White B, Bauer EA, Goldsmith LA, et al. Guidelines for clinical trials in systemic sclerosis (scleroderma). Arthritis Rheum. 1995;38(3):351–360.10.1002/(ISSN)1529-0131
   PubMedGoogle Scholar
• Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLOS ONE. 2016;11(10):e0163894.10.1371/journal.pone.0163894
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11):2437–2444.10.1002/(ISSN)1529-0131
   PubMed Web of Science ®Google Scholar
• Medsger TA Jr. Classification, prognosis. In: Clements P, Furst D, editors. Systemic sclerosis. Philadelphia (PA): Lippincot Williams and Wilkins; 2004. p. 17–28.
   Google Scholar
• Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum. 2001;44(12):2828–2835.10.1002/(ISSN)1529-0131
   PubMed Web of Science ®Google Scholar
• Moazedi-Fuerst F, Kielhauser S, Bodo K, et al. Dosage of rituximab in systemic sclerosis: 2-year results of five cases. Clin Exp Dermatol. 2015;40(2):211–212.10.1111/ced.2015.40.issue-2
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol. 2010;6(10):578–587.10.1038/nrrheum.2010.104
   PubMed Web of Science ®Google Scholar
• Ingegnoli F, Gualtierotti R. A systematic overview on the use and relevance of capillaroscopy in systemic sclerosis. Expert Rev Clin Immunol. 2013;9(11):1091–1097.10.1586/1744666X.2013.849198
   PubMed Web of Science ®Google Scholar
• Smith V, Pizzorni c, Riccieri V, et al. Stabilization of microcirculation in patients with early systemic sclerosis with diffuse skin involvement following rituximab treatment: an open-label study. J Rheumatol. 2016;43(5):995–996.10.3899/jrheum.151018
   PubMed Web of Science ®Google Scholar